The Israeli solution for the most difficult cancers
An article about Alpha Tau Medical (DRTS), a company developing an innovative cancer treatment using alpha radiation. Founded at Tel Aviv University and based in Jerusalem, the company is traded on Nasdaq. The article presents the technology, trial achievements, and business potential, highlighting the expected turning point in the company's valuation.
This article presents Alpha Tau Medical, a company developing an innovative cancer treatment called Alpha DaRT. The company, founded at Tel Aviv University and based in Jerusalem, is traded on Nasdaq under the symbol DRTS and on the Tel Aviv Stock Exchange under the symbol Darts. The treatment is based on alpha radiation inserted directly into the tumor, unlike beta or gamma radiation, and is suitable for all types of solid tumors, including the most difficult ones such as brain, pancreas, lungs, and breast. The main advantage is a short range of effect that makes the radiation lethal to cancer cells without harming healthy tissues. The article emphasizes that the company is led by CEO Uzi Sofer, who previously led Brainsway to public success. Trials have shown positive results, including complete disappearance of the tumor in two out of three patients in a trial for recurrent brain cancer. The company has received initial approvals in Israel and Japan, and is in advanced trial stages in the US. The article notes that the company's valuation stands at about one billion dollars, relatively low compared to other cancer companies, but predicts a significant breakthrough following expected FDA approvals, entry into the Japanese market, and critical trial results.